Navidea Biopharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€526.45 - Cost of goods sold
€105.67K - Gross profit
-€105.15K - SG&A expenses
€4.35M - R&D expenses
€4.40M - EBITDA
-€7.67M - D&A
€101.34K - EBIT
-€8.79M - Interest expenses
€757.38K - EBT
-€7.43M - Tax expenses
-€7.43M - Net income
-€1.02M
Cash flow statement
- Net deferred tax
€159.71K - Non-cash items
€5.28M - Changes in working capital
-€48.90K - Operating cash flow
-€8.38M - Capex
€166.83K - Other investing cash flow
€583.41 - Net investing cash flow
-€145.24K - Total cash dividends paid
€0.00 - Issuance of common stock
€1.41M - Debt repayment
-€524.96K - Other financing cash flow
€1.38M - Net financing cash flow
€859.37K - Foreign exchange effects
€0.00 - Net change in cash
-€635.17K - Cash at end of period
€3.34M - Free cash flow
-€8.22M
Balance sheet
- Cash and cash equivalents
€3.34M - Cash and short-term investments
€3.34M - Total receivables
€26.64K - Inventory
€397.64K - Other current assets
€126.52K - Total current assets
€3.89M - Property, plant & equipment
€103.03K - Goodwill
€0.00 - Intangible assets
€918.80K - Long-term investments
€0.00 - Other non-current assets
€10.16K - Total non-current assets
€1.03M - Total assets
€4.92M - Accounts payable
€1.79M - Short-term debt
€1.09M - Other current liabilities
€3.72M - Total current liabilities
€6.89M - Long-term debt
€232.16 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€604.36K - Total liabilities
€7.49M - Common stock
€251.21K - Retained earnings
-€333.05M - Other equity
-€2.82M - Total equity
-€2.57M - Total liabilities and shareholders' equity
€4.92M
Company information
- Market capitalization
€8.54K - Employees
11 - Enterprise Value
€509.82K
Company ratios
- Gross margin
-
-19,972.8% Much better than peer group: -24,256.3% - EBITDA margin
-
-1,457,401.0% Much better than peer group: -1,804,991.4% - EBIT margin
-
-1,668,791.0% Much better than peer group: -1,770,022.8% - EBT margin
-
-1,411,062.5% Much better than peer group: -1,527,349.3% - Net margin
-
-193,849.2% Much better than peer group: -1,721,861.8% - ROE
-
39.7% Much better than peer group: -747.0% - ROA
-
-20.7% Much better than peer group: -657.4% - Asset turnover
-
0.0% Much worse than peer group: 23.3% - FCF margin
-
-1,624,107.7% Much better than peer group: -1,758,667.2% - FCF yield
-100,161.8% - Efficiency ratio
1,457,501.0% - Net sales per employee
-
€47.86 - Net income per employee
-
-€92.77K